Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- Depression scores
研究概览
简要总结
This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants.
详细描述
This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants. Retrospective and prospective data will be collected on all subjects before and after pharmacogenetic recommendations have been made. Retrospective data will be collected for the previous 12 months before pharmacogenetic recommendations are made and prospective data will be collected for 12 months after pharmacogenomic recommendations have been made.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be taking either an anti-depressant or an anti-psychotic medication
- •Must provide informed consent
- •Must have Avera Health Plans insurance coverage
- •Must have three months of participation in the Avera Care Coordination Program
排除标准
- •Must not be pregnant or breastfeeding
- •Must not have an active and/or unstable diagnosis of substance abuse
- •Must not have a primary diagnosis of dementia, bulimia, or anorexia nervosa disorder
- •Must not have had a previous pharmacogenetic evaluation
结局指标
主要结局
Depression scores
时间窗: 12 months
Compare depression scores at baseline and following pharmacogenetic-guided medication recommendation
次要结局
- Economic impact of pharmacogenetic testing(12 months)